Mylan Amnesteem Revenue Falls 39%, But Isotretinoin Market Share Stable
Executive Summary
Mylan Amnesteem quarterly revenue fell by more than a third even though the acne drug's share of the isotretinoin market remains fairly stable in the face of increasing competition